This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Launches Firdapse In The European Union

NOVATO, Calif., April 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapseā„¢ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).  Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.  Firdapse received marketing approval in the E.U. for the treatment of LEMS in December 2009 and is the first approved treatment for this indication, thereby conferring orphan drug protection and providing ten years of market exclusivity in Europe.

"The launch of Firdapse brings the first specifically approved treatment option for LEMS to patients in the E.U. and marks our fourth commercial product on the market.  We look forward to meeting with the FDA in the second quarter of 2010 to determine the necessary regulatory path for Firdapse in the U.S., and we also continue to evaluate the best development strategy for this product in other indications in the U.S. and Europe," said Jean-Jacques Bienaime,  Chief Executive Officer of BioMarin.  "We remain committed to the advancement of our product pipeline and anticipate several notable upcoming milestones including results from the Phase I/II GALNS trial this current quarter and results from the Phase II PEG-PAL trial and Phase I trial of BMN-195 for Duchenne muscular dystrophy, both in the third quarter of 2010."

About LEMS

Lambert Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disease with the primary symptoms of muscle weakness.  Muscle weakness in LEMS is caused by autoantibodies to voltage gated calcium channels leading to a reduction in the amount of acetylcholine released from nerve terminals.  The prevalence of LEMS is estimated at four to ten per million, or approximately 2,000 to 5,000 patients in the EU and 1,200 to 3,100 patients in the U.S.  Approximately 50 percent of LEMS patients diagnosed have small cell lung cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMRN $67.53 0.76%
AAPL $93.97 -0.32%
FB $100.89 -0.11%
GOOG $681.27 -0.42%
TSLA $159.68 11.00%


Chart of I:DJI
DOW 15,714.70 -200.04 -1.26%
S&P 500 1,834.30 -17.56 -0.95%
NASDAQ 4,260.30 -23.2920 -0.54%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs